USFDA issues 2 observations for Piramal Pharma Bethlehem Facility
Piramal Pharma has announced that the US Food and Drug Administration (USFDA) has concluded a Good Manufacturing Practices (GMP) Inspection with two observations at the Company's Bethlehem facility.The inspection was held from 18th September 2023 to 27th September 2023."On conclusion of the inspection, a Form-483 was issued with 2 observations," the Company informed in a BSE filing.For...
Piramal Pharma has announced that the US Food and Drug Administration (USFDA) has concluded a Good Manufacturing Practices (GMP) Inspection with two observations at the Company's Bethlehem facility.
The inspection was held from 18th September 2023 to 27th September 2023.
"On conclusion of the inspection, a Form-483 was issued with 2 observations," the Company informed in a BSE filing.
For more details, check out the link given below:
Piramal Pharma Gets 2 USFDA Observations For Bethlehem Facility
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd